natgillin/translations-raw huggingface dataset:
In phase 3 studies, pre-meal administration of canagliflozin 300 mg provided a greater reduction in postprandial glucose excursion than observed with the 100 mg dose.
V študijah faze III je odmerek 300 mg kanagliflozina pred obrokom omogočil bolj obsežno zmanjšanje nihanja koncentracije glukoze v krvi po obroku kot odmerek 100 mg.
In Phase 3 studies, upon treatment with Tecfidera mean lymphocyte counts decreased on average by approximately 30% of their baseline value over the first year with a subsequent plateau.
V študijah 3. faze se je po zdravljenju z zdravilom Tecfidera v prvem letu srednje število limfocitov povprečno zmanjšalo za približno 30 % izhodiščne vrednosti, nato pa je doseglo konstantno raven.
In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2 – 2.5 mg.
V študijah faze I za ugotavljanje odmerka pri bolnikih z blago do zmerno hiperkalciemijo, povzročeno s tumorjem (TIH), so bili testirani učinkoviti odmerki v razponu približno 1,2–2,5 mg.
In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2-2.5 mg.
V študijah faze I za ugotavljanje odmerka pri bolnikih z blago do zmerno hiperkalciemijo, povzročeno s tumorjem (TIH), so bili testirani učinkoviti odmerki v razponu približno 1,2–2,5 mg.
In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2-2.5 mg.
V študijah I. faze za ugotavljanje odmerka pri bolnikih z blago do zmerno hiperkalciemijo, povzročeno s tumorjem (TIH), so bili testirani učinkoviti odmerki v razponu približno 1,2-2,5 mg.
In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2–2.5 mg.
V študijah faze I za ugotavljanje odmerka pri bolnikih z blago do zmerno hiperkalciemijo, povzročeno s tumorjem (TIH), so bili testirani učinkoviti odmerki v razponu približno 1,2–2,5 mg.
In Phase I studies in healthy subjects, between-subject CVb% for AUC and Cmax ranged from ~20 to 40% and C from 30 to 65% across studies.
V študijah I. faze pri zdravih preiskovancih je bil interindividualni CVb% AUC in Cmax med študijami od ~20 do 40 % in C od 30 do 65 %.
In phase I studies the exposure (AUC) of dabigatran after the oral administration of Pradaxa is approximately 2.7-fold higher in volunteers with moderate renal insufficiency (CrCL between 30-50 mL/min) than in those without renal insufficiency.
V raziskavah faze I je izpostavljenost (AUC) dabigatranu po peroralni aplikaciji zdravila Pradaxa pri prostovoljcih z zmerno ledvično insuficienco (CrCl 30 do 50 ml/min) približno 2,7-krat večja kot pri osebah brez ledvične insuficience .
In phase I studies the exposure (AUC) of dabigatran after the oral administration of Pradaxa is approximately 2.7-fold higher in volunteers with moderate renal insufficiency (CrCL between 30-50 mL/min) than in those without renal insufficiency.
V raziskavah I. faze je izpostavljenost (AUC) dabigatrana po peroralni aplikaciji zdravila Pradaxa pri prostovoljcih z zmerno ledvično insuficienco (CrCl 30 do 50 ml/min) približno 2,7 krat večja kot pri osebah brez ledvične insuficience.
In phase I studies the exposure (AUC) of dabigatran after the oral administration of Pradaxa is approximately 2.7-fold higher in volunteers with moderate renal insufficiency (CrCL between 30– 50 mL/min) than in those without renal insufficiency.
V raziskavah faze I je izpostavljenost (AUC) dabigatranu po peroralni aplikaciji zdravila Pradaxa pri prostovoljcih z zmerno ledvično insuficienco (CrCl 30 do 50 ml/min) približno 2,7-krat večja kot pri osebah brez ledvične insuficience .
In Phase II and III clinical trials, 276 patients with on-treatment genotypes have demonstrated that the predominant emerging mutations with tipranavir treatment are L33F/I/V, V82T/L and I84V.
V kliničnih preskušanjih II. in III. faze so izsledki pri 276 bolnikih z genotipi med zdravljenjem pokazali, da so mutacije ob zdravljenju s tipranavirjem L33F/I/V, V82T/L in I84V prevladujoče.
In phase II-III randomised double-blind monotherapy studies respective increases in QTc interval prolongation that exceeded change from baseline greater than >60 ms Fridericia-correction and Bazett-correction were 0 (0.0%) and 2 (0.3%) among placebo and 1 (0.1%) and 1 (0.1%) among Intuniv patients.
V randomiziranih dvojno slepih študijah monoterapije faze II-III se je interval QTc podaljšal od izhodišča za več kot 60 ms po Fridericijevem oziroma Bazettovem popravku pri 0 (0,0 %) oziroma 2 (0,3 %) bolnikih od tistih, ki so prejemali placebo, in pri 1 (0,1 %) oziroma 1 (0,1 %) bolniku od tistih, ki so jemali zdravilo Intuniv.
In Phase III clinical studies, the frequency of notable increases in blood glucose with Brimica Genuair was low (0.1%) and similar to placebo.
V kliničnih študijah 3. faze zdravila Brimica Genuair je bila pogostost pomembnega povečanja glukoze v krvi nizka (0,1 %) in podobna ravni s placebom.
In Phase III clinical studies, the frequency of notable increases in blood glucose with Duaklir Genuair was low (0.1%) and similar to placebo.
V kliničnih študijah 3. faze zdravila Duaklir Genuair je bila pogostost pomembnega povečanja glukoze v krvi nizka (0,1 %) in podobna ravni s placebom.
In phase III placebo-controlled clinical trials, the overall incidence of skin infections was similar in the placebo and the Prolia groups: in postmenopausal women with osteoporosis (placebo [1.2%, 50 out of 4,041] versus Prolia [1.5%, 59 out of 4,050]); in men with osteoporosis (placebo [0.8%, 1 out of 120] versus Prolia [0%, 0 out of 120]); in breast or prostate cancer patients receiving hormone ablation (placebo [1.7%, 14 out of 845] versus Prolia [1.4%, 12 out of 860]).
V kliničnih, s placebom kontroliranih preskušanjih III. faze je bila skupna incidenca okužb kože pri ženskah po menopavzi z osteoporozo primerljva pri skupini s placebom in z zdravilom Prolia (placebo: 1,2 %, 50 od 4.041; Prolia: 1,5 %, 59 od 4.050); pri moških z osteoporozo (placebo: 0,8 %, 1 od 120; Prolia: 0 %, 0 od 120); pri bolnicah oz. bolnikih z rakom na dojki ali na prostati, zdravljenih z ablacijo hormonov (placebo: 1,7 %, 14 od 845; Prolia: 1,4 %, 12 od 860).
In phase III placebo-controlled studies, the incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with Tecfidera or placebo, respectively.
V s placebom nadzorovanih študijah 3. faze je bila incidenca okužb (60 % v primerjavi s 58 %) in resnih okužb (2 % v primerjavi z 2 %) podobna pri bolnikih, zdravljenih z zdravilom Tecfidera in placebom.
In Phase III RESIST trials, the frequency of transaminase elevations was significantly increased in the tipranavir with ritonavir arm compared to the comparator arm.
V preskušanjih III. faze RESIST je bila pogostnost povečanja ravni transaminaze v skupini, ki je prejemala tipranavir ob ritonavirju, pomembno večja kot v primerjalni skupini.
In Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN).
V študijah faze III so bolniki s sočasno okužbo z virusom hepatitisa B in/ali C smeli biti vključeni v raziskavo pod pogojem, da njihove izhodiščne vrednosti jetrnih testov niso presegle petkratne zgornje meje normale (ULN – upper limit of normal).
In Phase III studies, treatment-experienced patients (N = 114/699 or 16%; HBV=6 %, HCV=9 %, HBV+HCV=1 %) and treatment-naïve patients (N = 34/563 or 6 %; HBV=4%, HCV=2%, HBV+HCV=0.2 %) with chronic (but not acute) active hepatitis B and/or hepatitis C co-infection were permitted to enrol provided that baseline liver function tests did not exceed 5 times the upper limit of normal.
HCV = 2 %, HBV + HCV = 0,2 %) s sočasno kronično okužbo (vendar ne akutno) z aktivnim virusom hepatitisa B in/ali virusom hepatitisa C so bili lahko vključeni v študije faze III pod pogojem, da izhodiščne vrednosti testov jetrne funkcije niso presegale 5-kratne zgornje meje normalnih vrednosti.
In phenotypic analyses of patients in the resistance analysis population, 7 of 19 patients (37%) had HIV-1 isolates with reduced susceptibility to elvitegravir in the Genvoya group compared with HIV-1 isolates from 4 of 16 patients (25%) in the E/C/F/TDF group, HIV-1 isolates from 8 patients (42%) had reduced susceptibility to emtricitabine in the Genvoya group compared with HIV-1 isolates from 4 patients (25%) in the E/C/F/TDF group.
V fenotipskih analizah bolnikov populacije za analizo rezistence je imelo 7 od 19 bolnikov (37 %) izolate HIV-1 z zmanjšano občutljivostjo za elvitegravir v skupini z zdravilom Genvoya v primerjavi z izolati HIV-1 pri 4 od 16 bolnikov (25 %) v skupini E/C/F/TDF, izolati HIV-1 pri 8 bolnikih (42 %) pa so imeli zmanjšano občutljivost za emtricitabin v skupini z zdravilom Genvoya v primerjavi z izolati HIV-1 pri 4 bolnikih (25 %) v skupini E/C/F/TDF.
In piglets, due to the smaller dose volume used, less extended lesions were observed in the laboratory trials whereas only limited fibrosis has uncommonly been observed at time of slaughter.
Pri pujskih so bile zaradi manjšega volumna odmerka v laboratorijskih pogojih opažene manjše poškodbe, pri klanju pa so bile redko opažene omejene fibroze.
In piglets, intramuscular administration of tildipirosin (on three occasions in intervals of 4 days) at 8, 12 and 20 mg/kg bodyweight (2, 3 and 5 times the recommended clinical dose), resulted in transient slightly subdued behaviour in one piglet each from the 8 and 12 mg/kg bodyweight group and 2 piglets from the 20 mg/kg bodyweight group following the first or second injection.
Pri pujskih se je po intramuskularnem dajanju tildipirozina (trikrat v razmakih po 4 dni) v odmerkih 8, 12 in 20 mg/kg telesne teže (2-, 3- in 5-kratni priporočeni klinični odmerek) po prvem ali drugem odmerku pojavilo prehodno rahlo umirjeno vedenje pri enem pujsku v skupinah, ki sta prejemali po 8 in 12 mg/kg telesne teže, in pri dveh pujskih iz skupine, ki je prejemala po 20 mg/kg telesne teže.
In pigs, after a single oral dose of radiolabelled material >90% absorption was demonstrated.
Pri prašičih je bila po enem peroralnem odmerku radioaktivno označene snovi dokazana več kot 90 % absorpcija.
In pigs, after intramuscular administration, the mean plasma elimination half-life is approximately 2.5 hours.
Pri prašičih je srednja razpolovna doba izločanja po intramuskularnem dajanju približno 2,5 ure.
In pigs, Inflacam is used in non-infectious locomotor disorders (diseases that affect the ability to move) to reduce the symptoms of lameness and inflammation, for the relief of post-operative pain associated with minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Pri prašičih se zdravilo Inflacam uporablja za zdravljenje neinfektivnih lokomotornih obolenj (bolezni, ki prizadenejo gibalne sposobnosti živali) za zmanjševanje simptomov šepavosti in vnetja, za lajšanje bolečin pri manjših kirurških posegih na mehkih tkivih, kot je npr. kastracija, in kot podporna terapija v kombinaciji z antibiotiki pri zdravljenju bolezni po oprasitvi (kotitvi mladičev), kot so puerperalna septikemija in toksemija (sindrom mastitis-metritis-agalaktija).
In pigs, Metacam is used in non-infectious locomotor disorders (diseases that affect the ability to move) to reduce the symptoms of lameness and inflammation, for the relief of post-operative pain associated with minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome, a bacterial infection of the udder and/or the womb).
Pri prašičih se zdravilo Metacam uporablja za zdravljenje nenalezljivih lokomotornih obolenj (bolezni, ki prizadenejo gibalne sposobnosti živali) za zmanjševanje simptomov šepavosti in vnetja, za lajšanje bolečin pri manjših kirurških posegih na mehkih tkivih, kot je npr. kastracija, in kot podporna terapija v kombinaciji z antibiotiki pri zdravljenju bolezni po oprasitvi (kotitvi mladičev), kot so puerperalna septikemija in toksemija (sindrom mastitis-metritis-agalaktija, bakterijska okužba vimena in/ali maternice).
In pigs, Rheumocam is used in non-infectious locomotor disorders (diseases that affect the ability to move) to reduce the symptoms of lameness and inflammation, for the relief of post-operative pain associated with minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth)
Pri prašičih se zdravilo Rheumocam uporablja za zdravljenje neinfekcijskih bolezni gibal (bolezni, ki prizadenejo sposobnost gibanja) za zmanjšanje simptomov šepavosti in vnetja, za ublažitev pooperativnih bolečin, povezanih z manjšimi kirurškimi posegi na mehkih tkivih, kot je npr. kastracija, ter kot podporna terapija v kombinaciji z ustreznimi antibiotiki pri zdravljenju bolezni, ki nastopijo po oprasitvi (kotitvi), kot so npr. puerperalna septikemija in toksemija (sindrom mastitis-metritis
In pigs, serious adverse drug reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace.
Pri prašičih so resni neželeni učinki uporabe zdravila Econor v glavnem povezani s pasmo danski in/ali švedski landrace ter križanci teh pasem.
In pigs, the efficacy of Econor in the claimed indications was investigated in challenge studies (i.e. pigs were artificially infected with the bacteria) or in field studies (i.e. natural infections under farm conditions).
Pri prašičih so učinkovitost zdravila Econor pri omenjenih indikacijah proučevali v provokacijskih študijah (tj. prašiče se umetno okuži z bakterijami) ali v terenskih študijah (tj. pri naravnih okužbah v pogojih na kmetiji).
In pivotal phase III clinical trials the following medicinal products were routinely combined with ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti- platelet medicinal products.
V ključnih kliničnih študijah III. faze so naslednja zdravila rutinsko kombinirali z ivabradinom, ne da bi opažali težave z varnostjo: zaviralci angiotenzinske konvertaze, antagonisti angiotenzina II, antagonisti adrenergičnih receptorjev beta, diuretiki, antagonisti aldosterona, kratko in dolgodelujoči nitrati, zaviralci hidroksimetilglutaril koencim A (HMG CoA) reduktaze, fibrati, zaviralci protonske črpalke, peroralni antidiabetiki, aspirin ter druga antitrombocitna zdravila.
In pivotal studies conducted in patients undergoing PCI dyspnoea (including exertional dyspnoea) occurred more commonly in patients treated with cangrelor (1.3%) than clopidogrel (0.4%).
V osrednjih študijah, izvedenih pri bolnikih pred PKI, se je dispneja (vključno z dispnejo po naporu) pojavila pogosteje pri bolnikih, zdravljenih s kangrelorjem (1,3 %) kot pri bolnikih s klopidogrelom (0,4 %).
In pivotal studies conducted in patients undergoing PCI, events of acute renal failure (0.1%), renal failure (0.1%) and increased serum creatinine (0.2%) were reported to occur after administration of cangrelor in clinical trials.
V osrednjih študijah, izvedenih pri bolnikih, ki so jim opravili PKI, so po dajanju kangrelorja v kliničnih preskušanjih poročali o dogodkih akutne ledvične odpovedi (0,1 %), ledvične odpovedi (0,1 %) in povečanja kreatinina v serumu (0,2 %).
In pivotal studies conducted in patients undergoing PCI, GUSTO (Global Use of Strategies to Open Occluded Arteries), moderate and mild bleeding events were more common in patients treated with cangrelor than in patients treated with clopidogrel, see section 4.8.
V ključnih študijah, ki so jih opravili pri bolnikih, ki so jim opravili PKI, so bile zmerne in blage krvavitve GUSTO (Global Use of Strategies to Open Occluded Arteries) pogostejše pri bolnikih, zdravljenih s kangrelorjem, kot pri bolnikih, zdravljenih s klopidogrelom, glejte poglavje 4.8.
In pivotal studies conducted in patients undergoing PCI, there were more cardiac tamponades at 30 days with cangrelor (0.12%) than with clopidogrel (0.02%), (see section 4.8).
V osrednjih študijah, izvedenih pri bolnikih pred PKI, je bilo več srčnih tamponad po 30-dnevni uporabi kangrelorja (0,12 %), kot pri uporabi klopidogrela (0,02 %) (glejte poglavje 4.8).
In pJIA patients, the central volume of distribution was 50 ml/kg, the peripheral volume of distribution was 53 ml/kg, resulting in a volume of distribution at steady state of 103 ml/kg.
Pri bolnikih s pJIA je bil centralni volumen distribucije 50 ml/kg, periferni volumen distribucije pa 53 ml/kg, kar je vodilo do volumna distribucije v stanju dinamičnega ravnovesja 103 ml/kg.
In placebo controlled studies low antibody responses have been reported with a frequency (3.4%) similar to that of placebo (4.8%).
V študijah, kontroliranih s placebom, so o odgovoru z nizkim titrom protiteles poročali s pogostnostjo (3,4 %), podobno kot pri placebu (4,8 %).
In placebo controlled trials in a post-operative ICU population previously intubated and sedated with midazolam or propofol, Dexdor significantly reduced the requirement for both rescue sedative (midazolam or propofol) and opioids during sedation for up to 24 hours.
V s placebom nadzorovanih preskušanjih pri populaciji postoperativnih bolnikov na oddelkih za intenzivno nego, ki so bili predhodno intubirani in sedirani z midazolamom ali propofolom, je med sedacijo v času do 24 ur zdravilo Dexdor bistveno zmanjšalo potrebo tako po rešilnem sedativu (midazolamu ali propofolu) kot po opioidih.
In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % verses 1.5 %, respectively).
V kliničnih preskušanjih, kontroliranih s placebom (ki so trajali 6-12 tednov), pri starejših bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami (povprečna starost 78 let), je bilo 2-kratno povečanje incidence smrti pri bolnikih, zdravljenih z olanzapinom, v primerjavi z bolniki, zdravljenimi s placebom (3,5 % v primerjavi z 1,5 %).
In placebo-controlled clinical trials with abatacept, adverse reactions (ARs) were reported in 51.8% of abatacept-treated patients and 46.4% of placebo-treated patients.
V s placebom nadzorovanih kliničnih preskušanjih abatacepta so o neželenih učinkih poročali pri 51,8% bolnikov, ki so prejemali abatacept, in 46,4% bolnikov, ki so prejemali placebo.
In placebo-controlled clinical trials with intravenous abatacept, adverse reactions (ARs) were reported in 51.8% of abatacept-treated patients and 46.4% of placebo-treated patients.
V s placebom nadzorovanih kliničnih preskušanjih intravenske uporabe abatacepta so o neželenih učinkih poročali pri 51,8% bolnikov, ki so prejemali abatacept, in 46,4% bolnikov, ki so prejemali placebo.
In placebo-controlled clinical trials with intravenous abatacept, malignancies were reported in 29 of 2,111 abatacept-treated patients observed during 1,829 patient-years, and in 12 of 1,099 placebo-treated patients observed during 849 patient-years.
V s placebom nadzorovanih kliničnih preskušanjih intravenske uporabe abatacepta so o novotvorbah poročali pri 29 od 2.111 bolnikov, ki so prejemali abatacept in so jih spremljali 1.829 bolniških let ter pri 12 od 1.099 bolnikov, ki so prejemali placebo in so jih spremljali 849 bolniških let.
In placebo-controlled clinical trials with naltrexone / bupropion for the treatment of obesity in adult subjects, no suicides or suicide attempts were reported in studies up to 56 weeks duration with naltrexone / bupropion, and suicidal ideation was not more commonly reported in subjects treated with naltrexone / bupropion compared to placebo.
V s placebom nadzorovanih kliničnih preskušanjih z naltreksonom/bupropionom za zdravljenje debelosti pri odraslih preiskovancih niso poročali o samomorih ali poskusih samomora v študijah z naltreksonom/bupropionom, ki so trajale do 56 tednov, pri preiskovancih, ki so bili zdravljeni z naltreksonom/bupropionom, pa o samomorilnih mislih niso poročali pogosteje kot pri uporabi placeba.
In placebo-controlled RA studies with Kineret, treatment was associated with small reductions in the mean values for total white blood count and absolute neutrophil count (ANC).
V študijah RA z zdravilom Kineret, kontroliranih s placebom, je bilo zdravljenje povezano z majhnim znižanjem srednjih vrednosti vseh belih krvničk in absolutnega števila nevtrofilcev (ANC – „absolute neutrophil count“).
In placebo-controlled studies (studies 1 and 2), the incidence of transaminase elevations (>3 x upper limit of normal [ULN]) were similar between subjects in the ivacaftor and placebo treatment groups (see section 4.8).
V študijah, kontroliranih s placebom (študiji 1 in 2), je bila pogostnost zvišanja transaminaz (> 3 x zgornja meja normalnih vrednosti [ULN]) pri bolnikih, ki so se zdravili z ivakaftorjem, in v skupinah s placebom podobna (glejte poglavje 4.8).
In placebo-controlled studies in RA patients, the most frequently reported adverse reactions with Kineret were injection site reactions (ISRs), which were mild to moderate in the majority of patients.
V s placebom kontroliranih študijah pri bolnikih z RA so bili neželeni učinki pri zdravilu Kineret, o katerih so najpogosteje poročali, reakcije na mestu injiciranja (ISR – „injection site reaction“), ki so bile pri večini bolnikov blage do zmerne.
In placebo-controlled studies involving 1,842 adult patients with partial-onset seizures (1,282 patients treated with eslicarbazepine acetate and 560 treated with placebo), 50.7% of patients treated with eslicarbazepine acetate and 27.7% of patients treated with placebo experienced adverse reactions.
V študijah, nadzorovanih s placebom, v katerih je sodelovalo 1.842 odraslih bolnikov s parcialnimi epileptičnimi napadi (1.282 bolnikov je prejemalo eslikarbazepinacetat, 560 pa placebo), so se neželeni učinki pojavili pri 50,7% bolnikov, ki so prejemali eslikarbazepinacetat, in pri 27,7% bolnikov, ki so prejemali placebo.
In placebo-controlled studies involving 1,842 adult patients with partial-onset seizures (1,282) patients treated with eslicarbazepine acetate and 560 treated with placebo), 50.7% of patients treated with eslicarbazepine acetate and 27.7% of patients treated with placebo experienced adverse reactions.
V študijah, nadzorovanih s placebom, v katerih je sodelovalo 1.842 odraslih bolnikov s parcialnimi epileptičnimi napadi (1.282 bolnikov je prejemalo eslikarbazepinacetat, 560 pa placebo), so se neželeni učinki pojavili pri 50,7 % bolnikov, ki so prejemali eslikarbazepinacetat, in pri 27,7 % bolnikov, ki so prejemali placebo.
In placebo-controlled studies involving 1.842 adult patients with partial-onset seizures (1,282 patients treated with eslicarbazepine acetate and 560 treated with placebo), 50.7% of patients treated with eslicarbazepine acetate and 27.7% of patients treated with placebo experienced adverse reactions.
V študijah, nadzorovanih s placebom, v katerih je sodelovalo 1.842 odraslih bolnikov s parcialnimi epileptičnimi napadi (1.282 bolnikov je prejemalo eslikarbazepinacetat, 560 pa placebo), so se neželeni učinki pojavili pri 50,7% bolnikov, ki so prejemali eslikarbazepinacetat, in pri 27,7% bolnikov, ki so prejemali placebo.